Summit Therapeutics Share Discussion Threads

[wrecktangle] 03/8/2018 09:03

If the US hasn't logged this RNS yet then I suspect the price will go further north in their market. As it stands LSE has a massive advantage here - we are playing catch up from 40p arena. No brainer here if I have ever seen one. Just watch how this plays out today and over the next few sessions.

[sigora] 03/8/2018 09:00

so if you hold shares in the us listing makes sence to add here to average down ?

[wrecktangle] 03/8/2018 08:52

Their NASDAQ price is



$2.38 per share. That is the equivalent of 1.83GBP.

Whether this rises today and gets to the GBP equivalent or rises over the next few sessions, I don't care. You have to be in it to win it.

Let's see if the US pushes the NASDAQ:SMMT further upon opening later today. Good luck all, easy 2 bagger from here.

[someuwin] 03/8/2018 08:33

Does look very good value now. Especially as mkt cap is almost covered by cash.

[kirk 6] 03/8/2018 08:29

Looks like we will see £1.50 again shortly

[kirk 6] 03/8/2018 08:29

Getting quotes of over 50p now to buy

[welshshark] 03/8/2018 08:25

Managed to get in @41.9 huge news

[the canadian mounted] 03/8/2018 08:24

Trouble with many private investors is they are too busy chasing oil and gas companies.

[someuwin] 03/8/2018 08:24

Can't buy many.

[kirk 6] 03/8/2018 08:20

Looks and reads like a game changer just the market has cottoned on yet

[the canadian mounted] 03/8/2018 08:18

Strong buying and I believe this is now the start of the share price climbing back to sensible levels not just mirroring cash assets which was laughable.

[chrisatrdg] 03/8/2018 08:16

Is this RNS a game changer or just confirmation of what we already new current share price reaction suggests the latter.

Edit: Looks like I 'spoke too soon' fingers crossed.

[kirk 6] 03/8/2018 08:05

Excellent news but again doesn't do much for the share price

[waterloo01] 03/8/2018 07:45

This is the full data which details it's effect on the stools of patients and the effect on the microbiome and explains why it beats Vanco by 59% in recurrence.

[waterloo01] 03/8/2018 07:24

"Ridinilazole Reduced Recurrence Rates by 59% versus Standard of Care Vancomycin" this is excellent and a clear explanation of why in that it preserves the microbiome and backs up why it should be used as a 1st & 2nd line treatment.

[chrisatrdg] 02/8/2018 22:29

Lets hope tonights news will have a positive effect on the share price on AIM in the morning it looks to have done on NASDAQ as there was a late surge ending at $2.38 increase of 2.15%.I note there was a large transaction of 5,000 units at 15.57 at $2.3953.Regards to all.

Edit: Link to Summit Webb site on publication:

[kirk 6] 02/8/2018 20:49

Read well?

[football] 02/8/2018 19:21

Summit Therapeutics : Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile Infection

[football] 02/8/2018 19:09

Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin
Cheleste M. Thorpe , Anne V. Kane, Justin Chang, Albert Tai, Richard J. Vickers, David R. Snydman
Published: August 2, 2018

Abstract
Ridinilazole, a novel targeted antibacterial being developed for the treatment of C. difficile infection (CDI) and prevention of recurrence, was shown in a recent Phase 2 study to be superior to vancomycin with regard to the primary efficacy measure, sustained clinical response (SCR), with the superiority being driven primarily by marked reductions in the rates of CDI recurrence within 30 days. Tolerability of ridinilazole was comparable to that of vancomycin. The current nested cohort study compared the effects of ridinilazole and vancomycin on fecal microbiota during and after treatment among participants in the Phase 2 study. Changes in the microbiota were assessed using qPCR and high-throughput sequencing on participants’ stools collected at multiple time-points (baseline [Day 1], Day 5, end-of-treatment [EOT; Day 10], Day 25, end-of-study [EOS; Day 40], and at CDI recurrence). qPCR analyses showed profound losses of Bacteroides, C. coccoides, C. leptum, and Prevotella groups at EOT with vancomycin treatment, while ridinilazole-treated participants had a modest decrease in C. leptum group levels at EOT, with levels recovering by Day 25. Vancomycin-treated participants had a significant increase in the Enterobacteriaceae group, with this increase persisting beyond EOT. At EOT, alpha diversity decreased with both antibiotics, though to a significantly lesser extent with ridinilazole (p <0.0001). Beta diversity analysis showed a significantly larger weighted Unifrac distance from baseline-to-EOT with vancomycin. Taxonomically, ridinilazole had a markedly narrower impact, with modest reductions in relative abundance in Firmicutes taxa. Microbiota composition returned to baseline sooner with ridinilazole than with vancomycin. Vancomycin treatment resulted in microbiome-wide changes, with significant reductions in relative abundances of Firmicutes, Bacteroidetes, Actinobacteria, and a profound increase in abundance of Proteobacteria. These findings demonstrate that ridinilazole is significantly less disruptive to microbiota than vancomycin, which may contribute to the reduced CDI recurrence observed in the Phase 2 study.

Figures

[wildbunch] 02/8/2018 10:51

If c diff drug is perceived to be all that CEO says it is then there should be predators circling. If there are not then......?